hotspot -WSS

hotspot

author：knowledge 2025-09-06 04:12:47 - browse：917

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

leisure time

WSS

What to do when lifesaving products contribute to climate change

Why patients can’t get everything they want on drug pricing

The battle over 'scope creep' and who gets to be called 'doctor'

Roche’s Alnylam deal shows drug firms interested in heart drugs

Will the market for weight loss drugs really reach $100 billion?

Takeda, Janssen join wearable maker to measure scratching

focus

hotspot

focus

Peter Hotez and the public health issue of online harassment

Why patients can’t get everything they want on drug pricing

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Will the market for weight loss drugs really reach $100 billion?

New air purifier tech could be key to improving indoor air quality

As biotech industry slumps, bioscience job market is upside down

What does generative AI mean for health care? We asked experts

Senate panel puts off hardest PBM reforms for another day

Trump demands the U.S. pay no more for drugs than other countries … again

Former reverend arrested for allegedly killing 8

entertainment

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

BIO selects John Crowley as new CEO

STAT Report: Patient voices and perspectives

A new crop of companies is reshaping the health data economy

FDA investigates CAR

Rise in cancer among younger people worries and puzzles doctors

hotspot

leisure time

leisure time

hotspot